Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: Results of a multicenter trial

Investigative Radiology

Volumn 43, Issue 7, 2008, Pages 504-511

  Zech, Christoph J ^a   Grazioli, Luigi ^b   Breuer, Josy ^c   Reiser, Maximilian F ^a   Schoenberg, Stefan O ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BRESCIA   (Italy)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Focal nodular hyperplasia; Gadoliniumethoxybenzyl diethylenetriamine pentaacetic acid; Hepatobiliary contrast agents; Liver magnetic resonance imaging

Indexed keywords

GADOXETIC ACID; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM ETHOXYBENZYL DTPA; GADOLINIUM PENTETATE;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; CONTRAST; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; HEPATIC ARTERY; HEPATOGRAPHY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LIPID STORAGE; LIVER CELL; LIVER HYPERPLASIA; LIVER VEIN; MAJOR CLINICAL STUDY; MORPHOLOGY; MULTICENTER STUDY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NOISE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; SINGLE BLIND PROCEDURE; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; ADOLESCENT; AGED; COMPARATIVE STUDY; FEMALE; GERMANY; LIVER TUMOR; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; GERMANY; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 50949093592     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181705cd1     Document Type: Article

References (26)

1. Kondo F. Benign nodular hepatocellular lesions caused by abnormal hepatic circulation: etiological analysis and introduction of a new concept. J Gastroenterol Hepatol. 2001 ;16:1319-1328.
2. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focalnodular hyperplasia of the liver. Hepatology. 1985;5:1194-1200.
3. Brancatelli G, Federle MP, Grazioli L, et al. Focal nodular hyperplasia: CT findings with emphasis on multiphasic helical CT in 78 patients. Radiology. 2001;219:61-68.
4. Welch TJ, Sheedy PF, Johnson CM, et al. Focal nodular hyperplasia and hepatic adenoma: comparison of angiography, CT, US, and scintigraphy. Radiology. 1985; 156:593-595.
5. Carlson SK, Johnson CD, Bender CE, et al. CT of focal nodular hyperplasia of the liver. AJR Am J Roentgenol. 2000;174:705-712.
6. Weimann A, Ringe B, Klempnauer J, et al. Benign liver tumors: differential diagnosis and indications for surgery. World J Surg. 1997; 21:983-990.
7. Choi CS, Freeny PC. Triphasic helical CT of hepatic focal nodular hyperplasia: incidence of atypical findings. AJR Am J Roentgenol. 1998;170:391-395.
8. Hussain SM, Terkivatan T, Zondervan PE, et al. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics. 2004;24:3-19.
9. Mortele KJ, Praet M, Van Vlierberghe H, et al. Focal nodular hyperplasia of the liver: detection and characterization with plain and dynamic-enhanced MRI. Abdom Imaging. 2002;27:700-707.
10. Beets-Tan RG, Van Engelshoven JMA, Greve JWM. Hepatic adenoma and focal nodular hyperplasia: MR findings with superparamagnetic iron oxide-enhanced MRI. Clin Imaging. 1998;22:211-215.
11. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphological and functional information from MR imaging with gadobenate dimeglumine. Radiology. 2001;221:731-739.
12. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology. 2005; 236:166-177.
13. Savellano DH, Kostler H, Baus S, et al. Assessment of sequential enhancement patterns of focal nodular hyperplasia and hepatocellular carcinoma on mangafodipir trisodium enhanced MR imaging. Invest Radiol. 2004;39:305-312.
14. Grazioli L, Morana G, Kirchin MA, et al. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison. J Magn Reson Imaging. 2003;17:593-602.
15. Schneider G, Altmeyer K, Kirchin MA, et al. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)->en-hanced liver magnetic resonance imaging. Invest Radiol. 2007;42:105-115.
16. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology. 2005;234:468-478.
17. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275.
18. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467.
19. Zech CJ, Herrmann KA, Huber A, et al. High-resolution MR-imaging of the liver with T2-weighted sequences using integrated parallel imaging: comparison of prospective motion correction and respiratory triggering. J Magn Reson Imaging. 2004;20:443-450.
20. Scharitzer M, Schima W, Schober E, et al. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2005;29:181-190.
21. Ba-Ssalamah A, Schima W, Schmook MT, et al. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. AJR Am J Roentgenol. 2002; 179:1447-1456.
22. Vogl TJ, Hammerstingl R, Schwarz W, et al. Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology. 1996;198:881-887.
23. Paley MR, Mergo PJ, Torres GM, et al. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. AJR Am J Roentgenol. 2000;175:159-163.
24. Namkung S, Zech CJ, Helmberger T, et al. Superparamagnetic iron oxide (SPIO)-enhanced liver MR imaging with ferucarbotran: efficacy for characterization of focal liver lesions with T2-weighted FSE and T2*-weighted GRE Images. J Magn Reson Imaging. 2007;25: 755-765.
25. Döhr O, Hofmeister R, Treher M, et al. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol. 2007;42:830-841.
26. Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol. 2007;42:242-247.